Abstract 2339: Prevalence of MET expression, activating mutations of KRAS and IDH1/2, and ROS1 fusions in cholangiocarcinoma patient tumor samples.
Megan N. Thobe(University of Cincinnati), Richard A. Walgren(Eli Lilly (United States)), Larry E. Douglass(Wood Hudson Cancer Research Laboratory), Mary E. Lajiness(Eli Lilly (United States)), Darryl Ballard(Eli Lilly (United States)), Donna M. Farley(University of Iowa), Victoria L. Peek(Eli Lilly (United States)), Bruce M. Colligan(Wood Hudson Cancer Research Laboratory), Nathan A. Brooks(Eli Lilly (United States)), Julia Carter(Wood Hudson Cancer Research Laboratory), Christoph Reinhard(University of Bern), Gaowa Jin(Brunswick (United States)), Aaron M. Gruver(Eli Lilly (United States)), Aejaz Nasir(University Diagnostic Institute), Jessica A Baker(Eli Lilly (United States)), Raymond Gilmour(Eli Lilly (Spain)), Suzane L. Um(Eli Lilly (United States)), S. Betty Yan(Cardiovascular Institute Hospital), Andrew E. Schade(Eli Lilly (United States)), Jeremy R. Graff(United Therapeutics (United States)), Kelly M. Credille(Eli Lilly (United States))
Cited by 3
Related Papers
Incidence and functional consequences of <i>hMLH1</i> promoter hypermethylation in colorectal carcinoma
|Proceedings of the National Academy of Sciences|1998|1.9k
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity
|Journal of Clinical Investigation|2007|377
Elevated expression of <i>axin2</i> and <i>hnkd</i> mRNA provides evidence that Wnt/β-catenin signaling is activated in human colon tumors
|Proceedings of the National Academy of Sciences|2001|367